KEGG   DRUG: Tralokinumab
Entry
D09979                      Drug                                   
Name
Tralokinumab (USAN/INN);
Tralokinumab (genetical recombination) (JAN);
Tralokinumab-ldrm;
Adbry (TN);
Adtralza (TN)
Product
ADBRY (LEO Pharma)
Formula
C6374H9822N1698O2014S44
Exact mass
143784.6063
Mol weight
143873.30
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGLSWVRQA PGQGLEWMGW ISANNGDTNY
GQEFQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDS SSSWARWFFD LWGRGTLVTV
SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSSLGT KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS CPAPEFLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ
EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
(Light chain)
SYVLTQPPSV SVAPGKTARI TCGGNIIGSK LVHWYQQKPG QAPVLVIYDD GDRPSGIPER
FSGSNSGNTA TLTISRVEAG DEADYYCQVW DTGSDPVVFG GGTKLTVLGQ PKAAPSVTLF
PPSSEELQAN KATLVCLISD FYPGAVTVAW KADSSPVKAG VETTTPSKQS NNKYAASSYL
SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS
(Disulfide bridge: H22-H96, H149-H205, H263-H323, H369-H427, H228-H'228, H231-H'231, L22-L87, L136-L195, H136-L213)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 4490
ATC code: D11AH07
Product: D09979<JP/US>
Efficacy
Antiasthmatic, Anti-inflammatory, Anti-IL-13 antibody
  Disease
Atopic dermatitis [DS:H01358]
  Type
Monoclonal antibody
Comment
Treatment of asthma and inflammatory diseases
Target
IL13 [HSA:3596] [KO:K05435]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 D DERMATOLOGICALS
  D11 OTHER DERMATOLOGICAL PREPARATIONS
   D11A OTHER DERMATOLOGICAL PREPARATIONS
    D11AH Agents for dermatitis, excluding corticosteroids
     D11AH07 Tralokinumab
      D09979  Tralokinumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Dermatological Agents
  Dermatitis and Pruitus Agents
   Dermatitis and Pruitus Agents, Other
    Tralokinumab
     D09979  Tralokinumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  44  Allergic agents
   449  Miscellaneous
    4490  Miscellaneous
     D09979  Tralokinumab (USAN/INN); Tralokinumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09979  Tralokinumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09979  Tralokinumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL13
     D09979  Tralokinumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09979
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09979
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09979
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09979
Other DBs
CAS: 1044515-88-9
PubChem: 135626700
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system